Neonatal cortical hyperostosis secondary to prolonged use of prostaglandin E1 in a patient with pulmonary atresia

Pulmoner atrezili bir hastada uzun süreli prostaglandin kullanımda bağlı neonatal kortikal hiperostoz

Nazan Neslihan DOĞAN¹, Dilek DİLLİ¹, Melek PALA AKDOĞAN², Utku Arman ÖRÜN³, Hakan AYDIN⁴, Ayşegül ZENCİROĞLU¹

¹ Clinic of Neonatology, Dr. Sami Ulus Maternity and Children Training and Research Hospital, Ankara, Turkey
² Clinic of Radiology, Dr. Sami Ulus Maternity and Children Training and Research Hospital, Ankara, Turkey
³ Clinic of Pediatric Cardiology, Dr. Sami Ulus Maternity and Children Training and Research Hospital, Ankara, Turkey
⁴ Clinic of Cardiovascular Surgery, Dr. Sami Ulus Maternity and Children Training and Research Hospital, Ankara, Turkey

ABSTRACT
Pulmonary atresia (PA) is one of the uncommon forms of complex cyanotic cardiac diseases accounting for approximately 1% of them in the neonatal period (1). Complete obstruction of pulmonary valve is followed by a total obstruction of the right ventricular outflow. So, the newborns who suffer from this anomaly are ductus dependent to maintain a continuous and adequate pulmonary blood flow. As spontaneous closure of the ductus is expected after few hours or days after birth, the patency of ductus should be provided by prostaglandin E1 (PGE1) while the patient is awaiting cardiosurgical intervention (2). Intravenous PGE1 infusions were first used in 1975 in infants with obstructive right heart malformations (3). The recommended initial dose of PGE1 is 0.05-0.1 μg/kg/min, and the dose may be titrated according to the response of the infant. If a constricted ductus has opened the dose can be reduced to 0.002-

INTRODUCTION
Pulmonary atresia (PA) is one of the uncommon forms of complex cyanotic cardiac diseases accounting for approximately 1% of them in the neonatal period (1). Complete obstruction of pulmonary valve is followed by a total obstruction of the right ventricular outflow. So, the newborns who suffer from this anomaly are ductus dependent to maintain a continuous and adequate pulmonary blood flow. As spontaneous closure of the ductus is expected after few hours or days after birth, the patency of ductus should be provided by prostaglandin E1 (PGE1) while the patient is awaiting cardiosurgical intervention (2). Intravenous PGE1 infusions were first used in 1975 in infants with obstructive right heart malformations (3). The recommended initial dose of PGE1 is 0.05-0.1 μg/kg/min, and the dose may be titrated according to the response of the infant. If a constricted ductus has opened the dose can be reduced to 0.002-

ÖZ

Anahtar Kelimeler: Prostaglandin E1, kortikal hiperostoz, yenidoğan, siyanotik konjenital kalp hastalığı
0.05 μg/kg/min. PGE1 infusion is usually applied for a short time period. However, in some circumstances, such as low birth weight, sepsis or absence of a specialized pediatric cardiology, cardiovascular surgery and/or tertiary neonatal intensive care unit (NICU), the infusion duration may extend from weeks to months. At the onset of the PGE1 treatment, several side-effects may occur that are generally reversible once the therapy is discontinued. Complications of long-term PGE1 infusion have been defined such as cortical hyperostosis, gastric-outlet obstruction, fluid electrolyte imbalance and pseudo-Bartter syndrome (4-7). In this report, we presented a case of newborn with PA who developed cortical hyperostosis secondary to prolonged use of PGE1.

CASE REPORT

A 24-day-old male baby, who was delivered spontaneously in a regional hospital of Syria, was referred to our hospital. It was noted that the mother was not under routine prenatal care due to the ongoing civil war in Syria. After delivery the family had fled from Damascus for refuge in Turkey. On the second day of life, the baby was admitted to a level II NICU in a South-Eastern Turkish town of Urfa, because of cyanosis and respiratory distress. On physical examination, a murmur accompanying to cyanosis was detected; he was consulted to a pediatric cardiologist. Echocardiography revealed PA and PGE1 infusion was initiated at a dose of 0.05 μg/kg/min. On the 24th day of life, he was transferred to our NICU for cardiosurgical intervention. He weighed 3300 g and had no major dysmorphic features except a rough face. Both upper and lower limbs were swollen and painful. A 3/6 systolic murmur was detected on cardiac auscultation. Echocardiography confirmed PA, intact atrial septum, ventricular septal defect (7 mm) and ductal patency. Pediatric cardiologists suggested continuing the PGE1 infusion (0.05 μg/kg/min) until surgery. Cardiovascular surgeons planned to perform a Blalock-Taussig (BT) shunt. However, the surgery was postponed due to clinical sepsis with fever, respiratory distress, leukocytosis, and high C-reactive protein levels. Antibiotic therapy was started after obtaining blood culture. At follow-up, pain and swelling observed in both extremities gradually increased. The X-Rays of the long bones revealed an intense periosteal reaction with bilateral corticoperiosteal thickening of the diaphyses (Figure 1). Laboratory analyses were performed for differential diagnosis of cortical thickening. Electrolyte imbalance or any findings of gastric outlet obstruction were not noted. Serology tests for syphilis were negative. Alkaline phosphates level was 822 U/L with normal calcium, phosphate and 25-OH vitamin D levels. There was no history of vitamin A ingestion. The rest of the liver function tests were normal. Then, considering the duration of PGE1 infusion, our findings suggested prostaglandin osteopathy. It was estimated that cortical hyperostosis developed after the cumulative dose of PGE1 of 5702 μg/kg.

Acetaminoprophen was given for pain relief. Antibiotic therapy for sepsis was continued for 26 days and stopped after three negative blood cultures. Subsequently, modified BT shunt was performed at 50th day of life. The infant had a good recovery from surgery without need of PGE1 infusion. After discontinuing PGE1 infusion the pain and swelling of the limbs in addition to the roughness of the face gradually decreased. Control X ray graphs taken four weeks after surgery showed radiological regression of the corticoperiosteal thickening (Figure 2).

DISCUSSION

The most common and dose related side effects of PGE1 therapy are apnea (12%), flushing and edema (10%), bradycardia (7%) ± hypotension (4%), hyperthermia (14%). Less common side effects are seizures (4%), sepsis (2%), diarrhea (2%) and tachycardia (3%) (8). Respiratory depression, arrhythmias, congestive heart failure, wheezing, gastric regurgitation, bleeding, anuria, hematuria, thrombocytopenia, peritonitis, hypo/hyperkalemia, hypoglycemia and jitteriness are also reported (9). Recently, it was suggested that the lower initial dose of PGE1 of 20 ng/kg/min and a maintenance dose of 10 ng/kg/min caused much fewer complications, such as apnea, fever, and hypotension (10). PGE1 infusion was needed at high doses for a long time in our patient. Complications of long term (> two weeks) PGE1 infusion are cortical hyperostosis, gastric outlet obstruction and pseudo-Bartter syndrome (4-7,11). In the presented case, the reasons for the delay of surgery and long term (50 days) PGE1 infusions were late admission of the patient and severe sepsis attacks. After the 24th day of PGE1...
infusion, he developed fever, coarse skin, rough face, and painful swelling in the both upper and lower limbs. X-Ray studies showed cortical hyperostosis in the long bones and also both clavicles.

The cortical hyperostosis of the long bones seems to be related with the duration of PGE1 infusion. In a study, the rate of hyperostosis was reported as 42 percent among infants who received PGE1 infusion more than 30 days. Once the duration of infusion exceeds 60 days, hyperostosis rate increased to 100 percent (4). Talosi et al. reported that cortical hyperostosis developed after different cumulative doses (1584, 3384 and 4320 μg/kg) in their case series (9). In our patient, it was estimated that cortical hyperostosis developed after the cumulative dose of PGE1 of 5702 μg/kg. Most infants with cortical hyperostosis are diagnosed by physical examination with soft tissue swelling, tenderness, limited mobility, and irritability. X-Rays can confirm the presence of bone changes and soft tissue swelling. Histological examination of bones with cortical hyperostosis due to prostaglandin shows rapid formation of primitive bone, extensive resorption of the outer cortical surface and bone formation of the inner surface. These changes of the bones are associated with high alkaline phosphate concentrations (40). Physical and radiological findings of our patient were consistent with PGE1 related cortical hyperostosis.

The differential diagnosis of cortical hyperostosis includes congenital syphilis, Caffey disease (Infantile Cortical Hyperostosis), scurvy and hypervitaminosis A. If the cortical thickening is limited to a single bone; it may be secondary to trauma, tumor, or osteomyelitis (9).

In our case, syphilis was ruled out with the absence of clinical history and compatible serology. In hypervitaminosis A, cortical hyperostosis appears after many months or years of excessive ingestion of vitamin A. The cortical thickening seen in scurvy occurs during the healing process and usually does not affect such small infants. Infantile cortical hyperostosis also known as Caffey disease is characterized by acute inflammation of the periostium and the overlying soft tissue. The classic Caffey disease has an onset within the first 6 months of life, and the mandible is the most commonly involved bone (12). In this patient, the history of prolonged PGE1 utilization for maintaining ductal patency and normal mandible bone appearance in X-Ray exams suggested prostaglandin osteopathy rather than Caffey disease.

CONCLUSION

Since cortical hyperostosis occurs in prolonged utilization of PGE1, this pathology should be kept on mind especially if the infusion is needed more than two weeks. To prevent the potential complications, the goal of PGE1 usage in severe cyanotic cardiac lesions must be to interrupt the therapy as soon as possible.

REFERENCES


How to cite: